An AI scanned 400k Reddit posts and uncovered hidden Ozempic side effects. Researchers leveraged machine learning to analyze user-generated data and identify previously unlisted symptoms.
Invitris' phage therapy, a DeepTech startup, revolutionizes medicine by producing new drugs in 4 to 8 hours using a cell-free platform. Founder Dr. Patrick Grossmann calls this the "ChatGPT moment" for pharma, with AI radically transforming personalized therapies.
This paper introduces TRACE, a trajectory-aware, LLM-reasoning agent for molecular lead optimization, addressing the limitation of one-step molecular optimization. It formulates tool selection as a sequential decision-making problem over action trajectories, crucial for transforming early hit compounds into viable drug candidates. TRACE aims to improve ADMET-related properties through subtle structural refinement while preserving key molecular substructures.
MOLPAQ is a novel modular quantum-classical generator that creates interpretable molecules from quantum-generated latent patches, achieving 100% RDKit validity and high novelty and diversity. This approach significantly improves property control, such as QED and aromatic motif incidence, over classical generators.
OpenAI introduces GPT-Rosalind, a frontier reasoning model built to accelerate drug discovery, genomics analysis, and scientific research workflows. It aims to advance life sciences through its advanced AI capabilities.
AI is being utilized to scan 1,500 approved drugs for hidden brain-disease signals, aiming to cut research time for conditions like MND, Parkinson's, and dementia from decades to years. Researchers are exploring if existing medications could be repurposed as treatments for neurological conditions.
This research explores molecular representation learning by leveraging language models and incorporating domain-relevant auxiliary tasks. The aim is to enhance the understanding and predictive capabilities for molecular properties.
MolClaw is an autonomous AI agent designed for drug molecule evaluation, screening, and optimization. It features a three-tier hierarchical skill architecture, unifying over 30 specialized domain resources, and introduces MolBench, a new benchmark for this field.
This research addresses challenges in robust molecular property prediction under extreme out-of-distribution (OOD) scenarios crucial for AI-driven drug discovery. It proposes SCOPE-BENCH, a new benchmark for OOD performance evaluation, and POMA, a framework for multi-source adaptation to overcome limitations of existing methods.
The paper introduces InteractBind, a large-scale dataset of approximately 100k protein-ligand pairs, and a benchmark for fine-grained evaluation. It aims to assess whether models can localize binding sites and identify non-covalent interactions, addressing a gap in existing evaluations.
Este conteúdo apresenta o DrugPlayGround, um framework para avaliar e comparar o desempenho de Large Language Models (LLMs) na descoberta de medicamentos. Ele foca na geração de descrições textuais de características de medicamentos, sinergismo, interações proteína-medicamento e respostas fisiológicas, com a participação de especialistas para justificar as previsões dos LLMs.
Filippo Menolascina uses Co-Scientist to identify new liver disease treatments. The tool also helps explain why existing drugs only benefit certain patients.
This article unpacks Google DeepMind CEO Demis Hassabis's statement at Google I/O, where he declared the company's ambition to "solve all disease" through reimagining drug discovery. The Verge's newsletter discusses the implications and context of such a bold claim.